Roche CEO Warns Against 'Middle Ground' Approach To Combat Pricing Pressure
This article was originally published in Scrip
Executive Summary
Roche Holding AG's CEO Severin Schwan says the only surefire way to beat pricing pressures is to focus on "highly innovative medicines, differentiated medicines, medicines which provide significant value for patients". By doing this Roche has been "less exposed to price pressure not only in the US, but worldwide, and we see that in the numbers." The company reported third quarter sales on Oct. 22 that beat expectations.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.